KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to -$156.2 million.

  • Takeda Pharmaceutical's Gains from Investment Securities rose 2407.19% to -$156.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.1 billion, marking a year-over-year decrease of 441.99%. This contributed to the annual value of -$1.1 billion for FY2025, which is 2656.92% up from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Gains from Investment Securities of -$156.2 million as of Q4 2025, which was up 2407.19% from -$374.9 million recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Gains from Investment Securities registered a high of -$156.2 million during Q4 2025, and its lowest value of -$655.2 million during Q3 2022.
  • Over the past 5 years, Takeda Pharmaceutical's median Gains from Investment Securities value was -$334.7 million (recorded in 2023), while the average stood at -$338.8 million.
  • Data for Takeda Pharmaceutical's Gains from Investment Securities shows a peak YoY increase of 6303.64% (in 2021) and a maximum YoY decrease of 15819.33% (in 2021) over the last 5 years.
  • Over the past 5 years, Takeda Pharmaceutical's Gains from Investment Securities (Quarter) stood at -$250.9 million in 2021, then crashed by 63.45% to -$410.1 million in 2022, then grew by 17.08% to -$340.0 million in 2023, then surged by 39.51% to -$205.7 million in 2024, then grew by 24.07% to -$156.2 million in 2025.
  • Its last three reported values are -$156.2 million in Q4 2025, -$374.9 million for Q3 2025, and -$253.3 million during Q2 2025.